Results 1 to 10 of about 182 (69)

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research
Aim: To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.
Ronan Mahon, Santosh Tiwari, Mirja Koch, Matias Ferraris, Keith A Betts, Yan Wang, Sophie Gao, Pascal Proot   +7 more
doaj   +2 more sources

Two-stage matching-adjusted indirect comparison

BMC Medical Research Methodology, 2022
Background Anchored covariate-adjusted indirect comparisons inform reimbursement decisions where there are no head-to-head trials between the treatments of interest, there is a common comparator arm shared by the studies, and there are patient-level data
Antonio Remiro-Azócar
doaj   +1 more source

Matching-Adjusted Indirect Comparisons in the assessment of hemato-oncological drugs [PDF]

Farmacia Hospitalaria, 2021
Objective: Matching-Adjusted Indirect Comparison is a methodology that has been developed to assess new treatments vs alternatives when a direct comparison is not available through a randomized controlled trial.
Francisco Javier Parrondo-García, José Manuel Martínez-Sesmero, Javier De Castro-Carpeño, Araceli López-de las Heras, Alonso Fernández-Nistal   +4 more
doaj   +1 more source

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison

Rheumatology and Therapy, 2023
Introduction The efficacy of sarilumab and upadacitinib, in combination with disease-modifying antirheumatic drugs (DMARDs), was demonstrated in phase 3 clinical trials of patients with rheumatoid arthritis (RA) refractive to previous biologic DMARDs. In
Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R. LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey R. Curtis, Roy Fleischmann   +10 more
doaj   +1 more source

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Experimental Hematology & Oncology, 2022
Background There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be inappropriate, as the study
Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney, John Kuruvilla   +9 more
doaj   +1 more source

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

Dermatology and Therapy, 2023
Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials.
Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, José-Carlos Armario-Hita   +4 more
doaj   +1 more source

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses

BMC Cancer, 2018
Background In the absence of head-to-head trials comparing axitinib with cabozantinib or everolimus, the aim of this study was to conduct an indirect comparison of their relative efficacy in patients with metastatic renal cell carcinoma (mRCC), using ...
Irina Proskorovsky, Agnes Benedict, Sylvie Negrier, Danielle Bargo, Rickard Sandin, Krishnan Ramaswamy, Jigar Desai, Joseph C. Cappelleri, James Larkin   +8 more
doaj   +1 more source

Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes

BMC Medical Research Methodology, 2020
Background The objectives of the present study were to evaluate the performance of a time-to-event data reconstruction method, to assess the bias and efficiency of unanchored matching-adjusted indirect comparison (MAIC) methods for the analysis of time ...
Yawen Jiang, Weiyi Ni
doaj   +1 more source

Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma

Journal of Hematology & Oncology, 2021
Background In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of lisocabtagene maraleucel (liso-
David G. Maloney, John Kuruvilla, Fei Fei Liu, Ana Kostic, Yeonhee Kim, Ashley Bonner, Yixie Zhang, Christopher P. Fox, Guillaume Cartron   +8 more
doaj   +1 more source

Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer

Biomolecules, 2021
FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GN) are the most common chemotherapy regimens in first-line treatment of metastatic pancreatic cancer (PC).
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti   +8 more
doaj   +1 more source